Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform

Caris Life Sciences Raises $830 Million in Growth Equity Capital to Continue to Expand its Precision Medicine Platform
Accelerates Caris’ rapid growth as the market leader reshaping precision oncology through basic science research and the application of artificial intelligence to one of the largest clinico-genomic databases

Capital raise represents one of the largest private financings in precision medicine supported by a diverse, high-quality syndicate of leading investorsContinue reading

C-Path Welcomes Alphabet Clinical Policy and Strategy Head, Former FDA Commissioner to Board

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

Continue reading

TGen-led study of more than 70,000 individuals links dementia to smoking and cardiovascular disease 

Significantly, women impaired more by smoking; men impaired more by cardiovascular disease

PHOENIX, Ariz. — May 13, 2021 — In the largest study of the associations between smoking and cardiovascular disease on cognitive function, researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, found both impair the ability to learn and memorize; and that the effects of smoking are more pronounced among females, while males are more impaired by cardiovascular disease.

Continue reading

C-Path Announces Accelerated Data Sharing Collaboration with Tufts Medical Center

FDA Grant Supports Use of Real-World Data to Generate Real-World Evidence in Neonates

TUCSON, Ariz., May 12, 2021 — Critical Path Institute (C-Path) and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence (RWE) for neonatal drug development, from real-world neonate data (RWD). This activity, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). The data sharing collaboration and transfer also marks the fastest on record for C-Path — starting with the Data Contribution Agreement negotiations and receipt of the data in three months’ time this March.Continue reading